Company Of The Day: Pfizer

+15.05%
Upside
49.21
Market
56.62
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

A recently published study from Israel on booster shots of Pfizer (NYSE:PFE) and its partner BioNTech’s Covid-19 vaccine indicates that a fourth dose of the vaccine (second booster) lowered the risk of severe disease in the elderly, although protection against infection was apparently short-lived.

So What?

Relevant Articles
  1. Company Of The Day: Pfizer
  2. Should You Buy Pfizer Stock Ahead of Its Q3 Results?
  3. Pfizer’s Peer Appears To Be A Better Pharmaceuticals Pick
  4. Should You Buy Pfizer Stock After An Upbeat Q2?
  5. Should You Buy Pfizer Stock Ahead of Its Q2 Results?
  6. Should You Buy, Sell, Or Hold Pfizer Stock At $52?

The U.S. recently authorized a second booster for people aged 50 and older while Israel is offering the shot for people aged 60 years or older. The data could likely encourage people to come forward and get additional protection as new Covid-19 variants emerge.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

Returns Apr 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 PFE Return 1% -11% 61%
 S&P 500 Return 0% -5% 102%
 Trefis MS Portfolio Return 0% -8% 262%

[1] Month-to-date and year-to-date as of 4/7/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios

See all Trefis Price Estimates